Editorial

Microvascular Obstruction: The Bane of Myocardial Reperfusion

Obstrucción microvascular: el azote de la reperfusion miocárdica

Heerajnarain Bulluck\textsuperscript{a,b} and Derek J. Hausenloy\textsuperscript{a,b,c,d,*}

\textsuperscript{a}The Hatter Cardiovascular Institute, University College London, London, United Kingdom
\textsuperscript{b}The National Institute of Health Biomedical Research Centre, University College London Hospitals, London, United Kingdom
\textsuperscript{c}National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore
\textsuperscript{d}Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore, Singapore

Article history:
Available online 6 October 2015

The field of interventional cardiology has made significant progress over the past 3 decades in the management of patients with ST-segment elevation myocardial infarction (STEMI), with the introduction of thrombolysis and primary percutaneous coronary intervention as the mainstay of treatment, which has significantly reduced morbidity and mortality in these patients.\textsuperscript{1} However, despite these advances, in-hospital mortality remains high at approximately 5% to 6%, increasing to 7% to 18% at 1 year.\textsuperscript{2} This is partly due to myocardial injury and myocardioyte death, which paradoxically occurs despite achieving patency of the infarct-related epicardial coronary artery – termed ‘myocardial reperfusion injury’. Four types of myocardial reperfusion injury have been described, namely reperfusion-induced arrhythmias, myocardial stunning, microvascular obstruction (MVO), and lethal myocardial reperfusion injury.\textsuperscript{3} The former 2 entities are self-limiting and reversible. The latter 2 are irreversible and induce myocardioyte death and have been the focus of intense research over the past 3 decades. Crucially, there is currently no effective therapy for preventing these lethal forms of myocardial reperfusion injury.

Microvascular obstruction, which manifests clinically as coronary no-reflow in the infarct-related artery following primary percutaneous coronary intervention, has been defined as the “inability to reperfuse a previously ischemic region”.\textsuperscript{4} In a recent meta-analysis using patient-level data from more than 1000 patients, MVO by cardiovascular magnetic resonance imaging was found to be present in 54.9% of primary percutaneous coronary intervention patients despite the presence of normal coronary flow within the infarct-related artery post-primary percutaneous coronary intervention.\textsuperscript{5} That study concluded that MVO was an independent predictor of major adverse cardiovascular events and cardiac death, whereas infarct size as a percentage of the left ventricle was not independently associated with major adverse cardiovascular events.\textsuperscript{5} Therefore, there is a pressing need to investigate MVO as a therapeutic target for studies targeting reperfusion injury in STEMI patients.

The animal model of acute myocardial ischemia-reperfusion injury remains a fundamental research tool necessary for the translation of basic science knowledge into the clinical setting. The porcine heart has similar anatomic and hemodynamic characteristics to the human heart\textsuperscript{6} and therefore has become the preferred model in cardiovascular research.

In the article published in Revista Española de Cardiología, Hervas et al\textsuperscript{7} investigate the dynamics of MVO in the porcine heart using intracoronary Thioflavin-S (T-S). The main objectives of their study were 2-fold. Firstly, they wanted to provide evidence for the prerequisite of acute ischemia-reperfusion injury for the development of MVO and its temporal evolution. Secondly, they aimed to compare the intracoronary administration of T-S against 2 other conventional routes of administration of T-S (intraventricular and intra-aortic) to visual MVO. They used a porcine model of acute myocardial infarction by inflating an angioplasty balloon in the mid-left anterior descending coronary artery for 90 minutes followed by reperfusion. Intracoronary T-S solution was selectively infused into the proximal left anterior descending through a catheter at 1-minute, 1-week, and 1-month post-reperfusion. In the no-reperfusion group, an over-the-wire balloon was used and was left inflated 90 minutes. The T-S was then injected through the lumen of the over-the-wire balloon. In the control group, the angioplasty balloon was not inflated. Hearts were then arrested and excised for histological evaluation (visualization of T-S staining under fluorescent light for MVO and staining with 2,3,5-triphenyltetrazolium chloride for infarct size). The second part of their experiment was intra-aortic and intra-ventricular injection of T-S at 1 week following the same ischemia-reperfusion protocol. The main findings of their study were: a) MVO, defined as absence of T-S stain, occurred in all the reperfused hearts and as early as 1 minute after reperfusion, whereas none of the hearts in the nonreperfused group had MVO. The extent of MVO was largest in the 1-week reperfusion group and smallest in the 1-month reperfusion group; b) the signal intensity ratio between the areas of MVO and non-MVO in the reperfused territory was higher in the intracoronary group compared with the intra-aortic and intraventricular groups, providing better differentiation of MVO. The authors conclude that myocardial reperfusion plays a critical role in the development of MVO and hence the importance of this critical window in STEMI patients. Secondly, the intracoronary route for T-S administration allowed accurate
characterization of MVO when compared with the conventional intra-aortic and intraventricular routes of administration.

Hervas et al⁷ should be congratulated for their study, which provides interesting insights into the pathophysiology of MVO in the reperfused heart. Firstly, their study reinforces the notion that MVO is a consequence of myocardial reperfusion injury and therefore any future studies targeting the reduction of MVO should be initiated prior to reperfusion of the infarct-related artery in order to gain maximum cardioprotection. Khan et al⁸ recently reported in a cohort of 94 STEMI patients (21 presented late and had no reperfusion therapy) that MVO by cardiovascular magnetic resonance imaging was not exclusive to reperfusion therapy and was primarily related to duration of ischemia. However, coronary angiography was performed in only 15 of those patients and 2 patients had Thrombolysis in Myocardial Infarction (TIMI) flow 2 and 4 patients had TIMI flow 1 on the diagnostic images. It is highly likely that some of these patients already had intermittent reperfusion and ischemia and, given the significant number of patients having some form of spontaneous reperfusion with TIMI flow > 0, this would explain the occurrence of MVO in these patients.

T-S is a fluorescent dye used to assess the patency of the microvascular circulation by staining endothelial cells in patent vessels during reperfusion.⁹ Although Hervas et al⁷ showed that MVO by T-S staining occurs as early as 1 minute after reperfusion, their study would have been more robust if they had been able to use a second parameter such as carbon black and microspheres⁴⁰ or electron microscopy of the microvasculature and tissue characterization by cardiac magnetic resonance imaging to further characterize the areas of MVO.

Hervas et al⁷ also attempted to provide some insight into the temporal evolution of MVO at 1 minute, 1 week and 1 month post-reperfusion. Rochitte et al¹¹ had previously shown that the extent of MVO increased significantly over the first 48 hours following reperfusion in a canine model. Orn et al¹² have shown a higher prevalence of MVO by cardiovascular magnetic resonance imaging at 2 days than at 1 week in STEMI patients. Furthermore, a recent abstract by Carrick et al¹³ reported on serial scanning in 30 STEMI patients at 4 time points (4-12 hours, 3 days, 10 days and 6-7 months post-reperfusion). The amount of MVO was greatest at 4-12 hours and fell progressively over time and the amount of intramyocardial hemorrhage increased from 4-12 hours and peaked at 3 days. Therefore, the observation in this study that MVO reached its largest extent at 1 week is not accurate and additional time-points between 1-minute and 1-week would have provided a more accurate representation of the evolution of MVO.

T-S has always been predominantly administered via the intravenous, intra-atrial, intra-aortic or intraventricular route. However, the same group has already previously used intracoronary T-S administration in previous studies⁴⁴,¹⁵ but in this study provided direct comparison of the signal intensities for MVO detection compared with the intra-aortic and intraventricular routes of administration. The intracoronary route offered better definition between MVO and the reperfused tissue and this will no doubt be a valuable technique for future research studies on MVO.

Despite its limitations, this study by Hervas et al⁷ provides a platform for future research in this field. Although we know that MVO portends a poor prognosis,² little is known about the ideal timing for MVO imaging and the extent of MVO that best predicts outcome, and more work needs to be done on developing strategies to minimize MVO and on translating them to clinical practice to eventually improve outcome in these patients.

CONFLICTS OF INTEREST

None declared.

REFERENCES